Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 81 to 90 of 118 total matches.
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
potential should
use effective contraception during treatment with
toripalimab and for 4 months after ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
contraception while taking capivasertib
and for one month (women) or 4 months (men) after
stopping the drug ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction
Donislecel (Lantidra) for Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
that they
are not pregnant before receiving donislecel. They
should use an effective method of contraception before ...
The FDA has approved donislecel-jujn (Lantidra –
CellTrans), an allogeneic pancreatic islet
cellular therapy, for use in conjunction with
immunosuppression for treatment of adults with
type 1 diabetes who are unable to approach target
HbA1c because of current repeated episodes of
severe hypoglycemia despite intensive diabetes
management and education. Donislecel is the first
cell-based treatment to be approved in the US for
type 1 diabetes.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):63-4 doi:10.58347/tml.2024.1700d | Show Introduction Hide Introduction
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
pup weight,
and increased mortality. An effective form of
contraception is recommended during ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
a pregnancy test before starting evinacumab
and should use contraception during treatment and
for at least 5 ...
The FDA has approved evinacumab-dgnb (Evkeeza –
Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor,
for adjunctive IV treatment of homozygous familial
hypercholesterolemia (HoFH) in patients ≥12 years
old. Evinacumab is the first ANGPTL3 inhibitor to be
approved in the US.
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
. Females of reproductive potential and
their male partners should use effective contraception
during ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
. Females with childbearing
potential and their male partners should use effective
contraception during ...
Two cell-based gene therapies – exagamglogene
autotemcel (Casgevy – Vertex) and lovotibeglogene
autotemcel (Lyfgenia – Bluebird Bio) – have been
approved by the FDA for treatment of sickle cell
disease in patients ≥12 years old with recurrent vaso-occlusive
crises. They are the first gene therapies to
be approved in the US for use in sickle cell disease;
Casgevy is the first treatment to be approved in the
US that uses CRISPR/Cas9 gene-editing technology.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):9-10 doi:10.58347/tml.2024.1694a | Show Introduction Hide Introduction
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
age should be advised to
use effective contraception during treatment with
darolutamide and for one ...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.
Ripretinib (Qinlock) for GIST (online only)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
and their
male partners should use effective contraception
during treatment with ripretinib and for 1 week after ...
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
use adequate
contraception during treatment with ozanimod and for 3
months after stopping the drug ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.